At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
everolimusdrug
Likely dose
everolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Locally Advanced, Unresectable or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China.
In Brief
A Phase 4 clinical trial evaluating everolimus for Pancreatic Neuroendocrine Tumors. Completed, enrolled 61 participants across 5 sites.
Detailed Summary
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumors
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedJul 2016
Primary CompletionFeb 2024
TodayJul 2026
First PostedJul 25, 2016
Enrollment StartMar 14, 2016
Primary CompletionFeb 22, 2024
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 9.9 years ago
Interventions
everolimusdrug
Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.